气血通化方联合恩替卡韦对慢性乙型肝炎患者TBil、LSM及临床症状的影响

Effect of Qi and blood Tonghua prescription combined with entecavir on TBil,LSM and clinical symptoms in chronic hepatitis B patients

目的:探讨并验证在学术传承观点指导下的气血通化方在慢性乙型肝炎患者治疗中的应用效果。方法:将2021年1月至2023年6月在南昌市第九医院就诊50例慢性乙型肝炎患者分为对照组和观察组,每组25例,对照组患者采用恩替卡韦治疗,观察组联合中药气血通化方治疗,治疗24周后观察治疗前后TBil、LSM的变化及临床疗效。结果:治疗后观察组患者总胆红素(TBil)、肝脏硬度值(LSM)低于对照组,差异具统计学意义(P<0.05);治疗后观察组患者中医总症状积分低于对照组,差异具统计学意义(P<0.05);观察组不良反应总发生率4.35%(3/69),对照组7.25%(5/69),差异无统计学意义(P>0.05)。结论:在“气血通化”学术观点指导下,恩替卡韦联合气血通化方治疗更有助于肝纤维化、总胆红素及症状改善,提高临床疗效。

Objective:To explore and verify the application effect of qi and blood Tonghua prescription in the treatment of chronic hepatitis B patients under the guidance of academic inheritance views.Methods:All patients with chronic hepatitis B were treated in Nanchang No.9 Hospital from January 2021 to June 2023 and grouped for clinical control.There were 25 patients in each group.The control group was treated with entecavir,and the observation group was combined with Qi and blood prescription,and the efficacy was compared after 24 weeks of treatment.Results:The total bilirubin(total bilirubin,TBil)and liver hardness value(LSM)of the treatment observation group were lower than that of the control group,and the difference was significant(P<0.05).After treatment,the total symptom score of TCM in the observation group was lower than that in the control group,and the difference was significant(P<0.05).The overall incidence of adverse reactions in the observation group was 4.35%(3/69)and 7.25%(5/69)in the control group,without any significant difference(P>0.05).Conclusion:Under the guidance of the academic view of"Qi and blood Tonghua",the treatment of entecavir and Qi and blood Tonghua prescription is more conducive to the improvement of liver fibrosis,total bilirubin,and symptoms,and improve the clinical efficacy.